Literature DB >> 20034816

Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study.

B Cosmi1, C Legnani, A Iorio, V Pengo, A Ghirarduzzi, S Testa, D Poli, A Tripodi, G Palareti.   

Abstract

OBJECTIVE: This study aims to assess the predictive value of residual venous obstruction (RVO) for recurrent venous thrombo-embolism (VTE) in a study using D-dimer to predict outcome.
DESIGN: This is a multicentre randomised open-label study.
METHODS: Patients with a first episode of idiopathic VTE were enrolled on the day of anticoagulation discontinuation when RVO was determined by compression ultrasonography in those with proximal deep vein thrombosis (DVT) of the lower limbs. D-dimer was measured after 1 month. Patients with normal D-dimer did not resume anticoagulation while patients with abnormal D-dimer were randomised to resume anticoagulation or not. The primary outcome measure was recurrent VTE over an 18-month follow-up.
RESULTS: A total of 490 DVT patients were analysed (after excluding 19 for different reasons and 118 for isolated pulmonary embolism (PE)). Recurrent DVT occurred in 19% (19/99) of patients with abnormal D-dimer who did not resume anticoagulation and 10% (31/310) in subjects with normal D-dimer (adjusted hazard ratio: 2.1; p = 0.02). Recurrences were similar in subjects either with (11%, 17/151) or without RVO (13%, 32/246). Recurrent DVT rates were also similar for normal D-dimer, with or without RVO, and for abnormal D-dimer, with or without RVO.
CONCLUSIONS: Elevated D-dimer at 1 month after anticoagulation withdrawal is a risk factor for recurrence, while RVO at the time of anticoagulation withdrawal is not. Copyright 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20034816     DOI: 10.1016/j.ejvs.2009.11.022

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  14 in total

Review 1.  Predicting the risk of recurrent venous thromboembolism (VTE).

Authors:  Michael B Streiff
Journal:  J Thromb Thrombolysis       Date:  2015-04       Impact factor: 2.300

Review 2.  Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.

Authors:  Geoffrey D Barnes; Yogendra Kanthi; James B Froehlich
Journal:  Vasc Med       Date:  2015-04       Impact factor: 3.239

3.  Predictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence.

Authors:  Omer Araz; Fadime Sultan Albez; Elif Yilmazel Ucar; Bugra Kerget; Nafiye Yılmaz; Metin Akgun
Journal:  Lung       Date:  2017-06-15       Impact factor: 2.584

4.  Increased d-dimer levels predict cardiovascular mortality in patients with systolic heart failure.

Authors:  Ali Zorlu; Mehmet Birhan Yilmaz; Hasan Yucel; Gokhan Bektasoglu; Meltem Refiker Ege; Izzet Tandogan
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

Review 5.  Acute pulmonary embolism. Part 2: treatment.

Authors:  Josien van Es; Renée A Douma; Victor E A Gerdes; Pieter W Kamphuisen; Harry R Büller
Journal:  Nat Rev Cardiol       Date:  2010-09-14       Impact factor: 32.419

Review 6.  Extended anticoagulation for unprovoked venous thromboembolism: a majority of patients should be treated.

Authors:  Clive Kearon
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

7.  Residual Vein Thrombosis Echogenicity Is Associated to the Risk of DVT Recurrence: A Cohort Study.

Authors:  Bruna M Mazetto; Fernanda L A Orsi; Sandra A F Silveira; Luis F Bittar; Mariane M C Flores-Nascimento; Kiara C S Zapponi; Marina P Colella; Erich V de Paula; Joyce M Annichino-Bizzacchi
Journal:  Clin Appl Thromb Hemost       Date:  2017-04-10       Impact factor: 2.389

Review 8.  Recurrent venous thromboembolism: what is the risk and how to prevent it.

Authors:  Gualtiero Palareti
Journal:  Scientifica (Cairo)       Date:  2012-09-17

9.  A systematic review of the utility of residual vein obstruction studies in primary and secondary venous thrombosis.

Authors:  Murali Janakiram; Matthew Sullivan; Marina Shcherba; Shuang Guo; Henny H Billett
Journal:  Thrombosis       Date:  2013-11-19

10.  A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study protocol for a mixed-methods study.

Authors:  Joanna D Smith; Jessica Baillie; Trevor Baglin; Gareth O Griffiths; Angela Casbard; David Cohen; David A Fitzmaurice; Kerenza Hood; Peter Rose; Alexander T Cohen; Miriam Johnson; Anthony Maraveyas; John Bell; Harold Toone; Annmarie Nelson; Simon I Noble
Journal:  Trials       Date:  2014-04-12       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.